Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Small Cell Lung Carcinoma | 10 | 2025 | 454 | 2.380 |
Why?
|
Lung Neoplasms | 30 | 2025 | 13594 | 2.080 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 16 | 2024 | 5434 | 1.620 |
Why?
|
Antibodies, Bispecific | 1 | 2025 | 205 | 0.790 |
Why?
|
Immunoconjugates | 4 | 2024 | 976 | 0.780 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2023 | 878 | 0.700 |
Why?
|
Early Detection of Cancer | 5 | 2022 | 3238 | 0.700 |
Why?
|
Carcinoma, Small Cell | 1 | 2020 | 419 | 0.580 |
Why?
|
Costs and Cost Analysis | 1 | 2017 | 1669 | 0.380 |
Why?
|
Nervous System Diseases | 1 | 2020 | 1665 | 0.330 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 11886 | 0.300 |
Why?
|
Antineoplastic Agents | 5 | 2024 | 13698 | 0.280 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3671 | 0.280 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2019 | 4064 | 0.260 |
Why?
|
Mutation | 4 | 2023 | 30266 | 0.240 |
Why?
|
Kidney Medulla | 3 | 2003 | 169 | 0.220 |
Why?
|
Carcinoma, Large Cell | 1 | 2023 | 114 | 0.210 |
Why?
|
Indazoles | 1 | 2024 | 306 | 0.210 |
Why?
|
Carcinoid Tumor | 1 | 2023 | 224 | 0.200 |
Why?
|
Membrane Transport Proteins | 3 | 2003 | 1038 | 0.190 |
Why?
|
Carbolines | 2 | 2020 | 295 | 0.190 |
Why?
|
Urea | 2 | 2003 | 448 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2024 | 567 | 0.180 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2023 | 342 | 0.170 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2023 | 3554 | 0.160 |
Why?
|
Benzamides | 1 | 2024 | 1387 | 0.160 |
Why?
|
Mass Screening | 4 | 2022 | 5457 | 0.150 |
Why?
|
Type C Phospholipases | 1 | 1998 | 287 | 0.150 |
Why?
|
Teaching Rounds | 1 | 2022 | 282 | 0.150 |
Why?
|
Humans | 37 | 2025 | 768970 | 0.140 |
Why?
|
Endogenous Retroviruses | 1 | 2018 | 112 | 0.140 |
Why?
|
Immunotherapy | 2 | 2025 | 4756 | 0.140 |
Why?
|
Carcinoma in Situ | 1 | 2021 | 788 | 0.120 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2024 | 2433 | 0.120 |
Why?
|
Ketoconazole | 1 | 2015 | 97 | 0.120 |
Why?
|
Urethral Neoplasms | 1 | 2014 | 37 | 0.120 |
Why?
|
Interferons | 1 | 2018 | 720 | 0.120 |
Why?
|
Neoplasm Staging | 7 | 2023 | 11262 | 0.120 |
Why?
|
Adenocarcinoma | 2 | 2022 | 6401 | 0.110 |
Why?
|
Isoenzymes | 1 | 1998 | 1687 | 0.110 |
Why?
|
Amino Acid Substitution | 1 | 2017 | 1742 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 1 | 2024 | 4528 | 0.100 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1748 | 0.100 |
Why?
|
Homeostasis | 1 | 2003 | 3347 | 0.100 |
Why?
|
Taxoids | 1 | 2015 | 668 | 0.090 |
Why?
|
Membrane Proteins | 2 | 2025 | 7885 | 0.090 |
Why?
|
Medical Oncology | 2 | 2021 | 2350 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 3 | 2022 | 20776 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 5342 | 0.080 |
Why?
|
Kidney | 3 | 2003 | 7058 | 0.080 |
Why?
|
Gene Expression | 1 | 2021 | 7603 | 0.080 |
Why?
|
Neoplasms | 3 | 2024 | 22389 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2021 | 9442 | 0.070 |
Why?
|
T-Lymphocytes | 1 | 2025 | 10276 | 0.070 |
Why?
|
Hydrocortisone | 1 | 2015 | 1841 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10400 | 0.070 |
Why?
|
Immunity, Innate | 1 | 2018 | 3080 | 0.060 |
Why?
|
DNA | 1 | 2020 | 7214 | 0.060 |
Why?
|
Alleles | 1 | 2017 | 6901 | 0.060 |
Why?
|
Retrospective Studies | 7 | 2023 | 81903 | 0.060 |
Why?
|
Pneumonectomy | 2 | 2023 | 1159 | 0.060 |
Why?
|
Male | 13 | 2024 | 365203 | 0.050 |
Why?
|
Kidney Concentrating Ability | 1 | 2003 | 34 | 0.050 |
Why?
|
Aged | 9 | 2024 | 171786 | 0.050 |
Why?
|
Female | 12 | 2024 | 397515 | 0.050 |
Why?
|
Biological Transport, Active | 1 | 2003 | 323 | 0.050 |
Why?
|
Angiotensins | 1 | 2003 | 141 | 0.050 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2024 | 330 | 0.050 |
Why?
|
Lung | 1 | 2020 | 10099 | 0.050 |
Why?
|
Middle Aged | 9 | 2024 | 223737 | 0.050 |
Why?
|
Uremia | 1 | 2003 | 202 | 0.050 |
Why?
|
Trophoblasts | 1 | 2023 | 223 | 0.050 |
Why?
|
Vasopressins | 1 | 2003 | 358 | 0.050 |
Why?
|
Urine | 1 | 2003 | 362 | 0.050 |
Why?
|
Cell Membrane Permeability | 1 | 2003 | 573 | 0.050 |
Why?
|
Prognosis | 2 | 2022 | 30046 | 0.040 |
Why?
|
Adult | 6 | 2024 | 223851 | 0.040 |
Why?
|
Camptothecin | 1 | 2024 | 600 | 0.040 |
Why?
|
Gene Rearrangement | 1 | 2024 | 1148 | 0.040 |
Why?
|
Technology | 1 | 2021 | 296 | 0.040 |
Why?
|
Antigens, Surface | 1 | 2023 | 1616 | 0.040 |
Why?
|
DNA Helicases | 1 | 2023 | 854 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2021 | 329 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39394 | 0.040 |
Why?
|
RNA, Antisense | 1 | 2018 | 136 | 0.040 |
Why?
|
Carboplatin | 1 | 2021 | 799 | 0.040 |
Why?
|
Membrane Glycoproteins | 2 | 2000 | 3713 | 0.040 |
Why?
|
Survival Analysis | 2 | 2021 | 10115 | 0.040 |
Why?
|
Rats | 4 | 2003 | 23786 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2020 | 6856 | 0.040 |
Why?
|
Morbidity | 1 | 2022 | 1757 | 0.030 |
Why?
|
Renal Insufficiency | 1 | 2003 | 812 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2018 | 9213 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2018 | 877 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2024 | 21188 | 0.030 |
Why?
|
Cisplatin | 1 | 2022 | 1661 | 0.030 |
Why?
|
Cranial Irradiation | 1 | 2018 | 395 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2021 | 864 | 0.030 |
Why?
|
Treatment Outcome | 5 | 2024 | 65480 | 0.030 |
Why?
|
United States | 2 | 2020 | 73186 | 0.030 |
Why?
|
Carrier Proteins | 2 | 2000 | 4939 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2024 | 2893 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2000 | 1369 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2024 | 59739 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2022 | 1970 | 0.030 |
Why?
|
Paclitaxel | 1 | 2021 | 1735 | 0.030 |
Why?
|
Doxorubicin | 1 | 2020 | 2234 | 0.030 |
Why?
|
Receptor, erbB-2 | 1 | 2024 | 2606 | 0.030 |
Why?
|
Mice, Nude | 1 | 2018 | 3631 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2018 | 2921 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8559 | 0.020 |
Why?
|
Trans-Activators | 1 | 2000 | 2858 | 0.020 |
Why?
|
Blotting, Western | 1 | 1998 | 5033 | 0.020 |
Why?
|
Gene Expression Regulation | 2 | 2000 | 11932 | 0.020 |
Why?
|
Dietary Proteins | 1 | 1995 | 960 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 2 | 1998 | 8144 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6805 | 0.020 |
Why?
|
Transcription, Genetic | 2 | 2000 | 7609 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2023 | 5804 | 0.020 |
Why?
|
Cohort Studies | 2 | 2022 | 41808 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2021 | 10765 | 0.020 |
Why?
|
Cytokines | 1 | 2023 | 7453 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2024 | 8055 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 5707 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5928 | 0.020 |
Why?
|
Quality Improvement | 1 | 2022 | 3860 | 0.020 |
Why?
|
Transcription Factors | 2 | 2023 | 12174 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12873 | 0.020 |
Why?
|
Societies, Medical | 1 | 2018 | 3968 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3629 | 0.020 |
Why?
|
Animals | 5 | 2018 | 169335 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 2015 | 2487 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 1998 | 11116 | 0.010 |
Why?
|
Cognition | 1 | 2022 | 7081 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2003 | 5892 | 0.010 |
Why?
|
Cloning, Molecular | 2 | 2000 | 4168 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8664 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2018 | 17173 | 0.010 |
Why?
|
Kidney Tubules, Collecting | 1 | 2000 | 163 | 0.010 |
Why?
|
Risk Assessment | 1 | 2021 | 24333 | 0.010 |
Why?
|
Luciferases | 1 | 2000 | 713 | 0.010 |
Why?
|
Mice | 2 | 2003 | 82072 | 0.010 |
Why?
|
Disease Progression | 1 | 2015 | 13674 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2000 | 1683 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2000 | 1498 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2000 | 1714 | 0.010 |
Why?
|
Dogs | 1 | 2000 | 3845 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 2000 | 17629 | 0.010 |
Why?
|
Diuresis | 1 | 1995 | 107 | 0.010 |
Why?
|
Models, Structural | 1 | 1995 | 340 | 0.010 |
Why?
|
Transfection | 1 | 2000 | 5763 | 0.010 |
Why?
|
Protein Structure, Secondary | 1 | 1995 | 1216 | 0.010 |
Why?
|
Adolescent | 1 | 2020 | 89244 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2000 | 3744 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1995 | 1990 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1995 | 1904 | 0.010 |
Why?
|
Xenopus laevis | 1 | 1995 | 966 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1995 | 2749 | 0.010 |
Why?
|
Oocytes | 1 | 1995 | 1172 | 0.010 |
Why?
|
Base Sequence | 1 | 2000 | 12430 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2000 | 5801 | 0.010 |
Why?
|
Rabbits | 1 | 1995 | 4774 | 0.000 |
Why?
|
Cell Line | 1 | 2000 | 15604 | 0.000 |
Why?
|
Cell Membrane | 1 | 1995 | 3659 | 0.000 |
Why?
|
Recombinant Proteins | 1 | 1995 | 6512 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1995 | 13427 | 0.000 |
Why?
|
Models, Biological | 1 | 1995 | 9499 | 0.000 |
Why?
|
Concepts
(167)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(35)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_